The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Cancer radiotherapy. Buy the report here.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Cancer radiotherapy is a key innovation area in immuno-oncology
Radiation therapy or radiotherapy is a type of cancer treatment that uses high-energy X-ray or ionising rays to eradicate the cancer cells. The two types of radiation therapy are external beam radiation therapy and internal radiation therapy. Cancer radiotherapy drugs (radiosensitizers) enhance radiation therapy’s efficacy.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 60 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of cancer radiotherapy.
Key players in cancer radiotherapy – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to cancer radiotherapy
|Company||Total patents (2010 - 2022)||Premium intelligence on the world's largest companies|
|Immunolight||135||Unlock Company Profile|
|Nanobiotix||117||Unlock Company Profile|
|Vertex Pharmaceuticals||110||Unlock Company Profile|
|Les Laboratoires Servier||69||Unlock Company Profile|
|HitGen||60||Unlock Company Profile|
|Pfizer||57||Unlock Company Profile|
|Omniox||44||Unlock Company Profile|
|Regeneron Pharmaceuticals||42||Unlock Company Profile|
|BioMarin Pharmaceutical||36||Unlock Company Profile|
|Tyme||31||Unlock Company Profile|
|MetiMedi Pharmaceuticals||29||Unlock Company Profile|
|Siemens||28||Unlock Company Profile|
|Gilead Sciences||23||Unlock Company Profile|
|E. Merck||21||Unlock Company Profile|
|Cancer Research Technology||21||Unlock Company Profile|
|Memorial Sloan Kettering Cancer Center||18||Unlock Company Profile|
|Aprogen pharmaceuticals||18||Unlock Company Profile|
|AbbVie||17||Unlock Company Profile|
|MorEx Development Partners LLP||17||Unlock Company Profile|
|Calidi Biotherapeutics||16||Unlock Company Profile|
|Fumedica||16||Unlock Company Profile|
|Adastra Pharmaceuticals||15||Unlock Company Profile|
|Cancer Research UK||14||Unlock Company Profile|
|Karyopharm Therapeutics||14||Unlock Company Profile|
|Bayer||13||Unlock Company Profile|
|Idera Pharmaceuticals||13||Unlock Company Profile|
|Providence St. Joseph Health||13||Unlock Company Profile|
|Shuttle Pharmaceuticals||12||Unlock Company Profile|
|Diffusion Pharmaceuticals||12||Unlock Company Profile|
|NH TherAguix||11||Unlock Company Profile|
|Daiichi Sankyo||11||Unlock Company Profile|
|Spectrum Pharmaceuticals||11||Unlock Company Profile|
|F. Hoffmann-La Roche||11||Unlock Company Profile|
|CLS Therapeutics||10||Unlock Company Profile|
|Afimmune Biopharma||10||Unlock Company Profile|
|PI Therapeutics||10||Unlock Company Profile|
|Help/Systems||10||Unlock Company Profile|
|Neonc Technologies||10||Unlock Company Profile|
|Firsthand Technology Value Fund||10||Unlock Company Profile|
|MEI Pharma||10||Unlock Company Profile|
|Centre National de la Recherche Scientifique||9||Unlock Company Profile|
|Takeda Pharmaceutical||9||Unlock Company Profile|
|Regulon||9||Unlock Company Profile|
|Alpha Tau Medical||8||Unlock Company Profile|
|Vascular Biogenics||8||Unlock Company Profile|
|GlycoMira Therapeutics||7||Unlock Company Profile|
|MiraDx||7||Unlock Company Profile|
|Del Mar Pharmaceuticals (BC)||7||Unlock Company Profile|
|PT Soho Global Health Tbk||7||Unlock Company Profile|
|Neumedicines||7||Unlock Company Profile|
Source: GlobalData Patent Analytics
Nanobiotix is one of the leading patent filers in cancer radiotherapy drugs. The company is involved in designing and manufacturing nanoparticles that safely enhance radiation therapy's efficacy in cancer treatment. The company’s lead asset is NBTXR3, which is based on hafnium oxide nanoparticle that is designed to destroy tumours when activated by radiation. Based on the success of NBTXR3, the company is also working on several other drug molecules with comparable properties.
In terms of application diversity, Aprogen pharmaceuticals is the top company, followed by MetiMedi Pharmaceuticals and Gilead Sciences. By means of geographic reach, Les Laboratoires Servier holds the top position. HitGen and BioMarin Pharmaceutical are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.